{'fraction_non_alphanumeric': 0.016726403823178016, 'fraction_numerical': 0.007168458781362007, 'mean_word_length': 5.161764705882353, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 1, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Current Literature in ADHD

A small sample of children, ages 5 to 15 years with Asperger’s Disorder, full Autism, or Pervasive Developmental Disorder—Not Otherwise Specified and ADHD symptoms were treated for 6 weeks with Atomoxetine and placebo with a one week wash out period in between. Symptoms were evaluated using parent and teacher questionnaires. Seven of the 16 children were considered responders to the Atomoxetine but not placebo. One child discontinued the study because of adverse events. This child was rehospitalized for violence while on Atomoxetine. However, prior episodes predated treatment. The authors report that response rates were similar to a large study of methylphenidate treatment for ADHD symptoms in autism with a lower rate of discontinuation because of side effects. They suggest further study is needed.